Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study

J Reprod Med. 2006 Jun;51(6):467-70.

Abstract

Objective: To evaluate the effects of botulinum toxin type Afor the treatment of provoked vestibulodynia.

Study design: Open-label, dose-escalation, pilot study. Primary outcome measure was a standard numeric pain rating scale of 0-10. Secondary measures were improvements in quality of life and change in medication use.

Results: The 7 patients who received 35 units of botulinum toxin type A had a baseline mean pain score (0-10) of 8.1 (SD = 0.70). Thirty days after treatment, these patients had a mean pain score of 2.9 (SD= 1.17). The duration of effect was 8 weeks, and there were no side effects. The 12 patients who received 50 units of botulinum toxin type A had a baseline mean pain score of 7.4 (SD = 0.10). Thirty days after treatment, these patients had a mean pain score of 1.8 (SD= 0.72). The duration of effect was 14 weeks, and there were no side effects. Significant improvement was also seen in medication use and quality of life for these patients.

Conclusion: This study provides further clinical evidence of the nociceptive effects of botulinum toxin type A in pelvic inflammatory pain-related disorders. Doubleblind, placebo-controlled trials to evaluate the efficacy of botulinum toxin in treating patients with provoked vestibulodynia are warranted.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Botulinum Toxins, Type A / administration & dosage*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Injections, Intramuscular
  • Middle Aged
  • Neurotoxins / administration & dosage*
  • Pain / drug therapy*
  • Pilot Projects
  • Vulvar Diseases / drug therapy*

Substances

  • Neurotoxins
  • Botulinum Toxins, Type A